Skip to main content

Table 3 The association between direction of serum phosphate changes and in-hospital mortality

From: Impact of serum phosphate changes on in-hospital mortality

Phosphate change (mg/dL)

N

In-hospital mortality

Model 1

Model2

Model 3

Model 4

≤ −2.8

2941

230 (7.8)

6.74 (4.91–9.26)

4.32 (3.07–6.08)

2.94 (2.02–4.28)

3.70 (2.62–5.23)

−2.7 to − 2.1

2281

76 (3.3)

2.74 (1.90–3.96)

2.42 (1.66–3.53)

2.20 (1.48–3.26)

2.48 (1.70–3.62)

−2.0 to −1.4

3519

90 (2.6)

2.09 (1.46–2.98)

2.00 (1.39–2.87)

1.79 (1.22–2.63)

2.05 (1.43–2.96)

−1.3 to −0.7

4358

76 (1.7)

1.41 (0.98–2.03)

1.39 (0.96–2.01)

1.27 (0.85–1.88)

1.43 (0.99–2.08)

−0.6 to 0

3782

47 (1.2)

1 (ref)

1 (ref)

1 (ref)

1 (ref)

0.1 to 0.6

3058

54 (1.8)

1.43 (0.96–2.12)

1.50 (1.01–2.24)

1.47 (0.95–2.27)

1.48 (0.99–2.21)

0.7 to 1.3

3101

76 (2.5)

2.00 (1.38–2.88)

2.02 (1.39–2.93)

2.39 (1.61–3.55)

2.08 (1.43–3.02)

1.4 to 2.0

2223

86 (3.9)

3.20 (2.23–4.58)

3.13 (2.17–4.52)

3.57 (2.41–5.29)

3.24 (2.24–4.70)

2.1 to 2.7

1432

86 (6.0)

5.08 (3.54–7.28)

4.87 (3.35–7.08)

5.48 (3.67–8.17)

4.81 (3.30–7.02)

≥ 2.8

1454

239 (16.4)

15.63 (11–36-21.51)

10.26 (7.26–14.49)

11.22 (7.76–16.24)

8.56 (6.03–12.15)

  1. Model 1: unadjusted
  2. Model 2: Adjusted for age, sex, race, principal diagnosis, Charlson comorbidities score, history of coronary artery disease, congestive heart failure, peripheral artery disease, stroke, diabetes mellitus, chronic obstructive pulmonary disease, cirrhosis, eGFR, AKI, the number of serum phosphate measurement during hospitalization, and length of stay
  3. Model 3: model 2 and the admission phosphate
  4. Model 4: model 2 and mean serum phosphate during hospitalization
  5. Convert serum phosphate from mg/dL to mmol/L by multiplying by 0.32